Sickle Cell Disease
L-Glutamine oral treatment with or without hydroxyurea reduces pain crises better than placebo in individuals with sickle cell disease.
In adults with sickle cell disease, higher daily opioid use may be associated with poorer health-related quality of life.
Olinciguat is a soluble guanylate cyclase stimulator currently in Phase 2 development.
In patients with sickle cell disease, review of intermittent pain diaries using a single random day per week or a single week per month was shown to be comparable to review of 5 months' worth of pain diaries.
The FDA has approved Endari to reduce acute complications of sickle cell disease in patients aged ≥5 years.
A new evidence-based classification system for chronic sickle cell disease pain was recently published.
Crizanlizumab therapy resulted in a significantly lower rate of sickle cell-related pain crises.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Examining the Efficacy of Different Oxygen Flow Rates for Cluster Headache Attacks
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Nonsinogenic Headache vs Chronic Rhinosinusitis Differential Diagnosis Based on SNOT-22 Patterns
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Factors Promoting Participation in Self-Management Training Program for Chronic Pain
- Gendered Perceptions of Socially Acceptable Pain Relief Strategies
- Majority of Internists Still Have Financial Ties to Industry